Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Loratadine Recommended to Be Approved as New Anti-allergic Drug
May 13, 2002
- Japanese, US, EU Patent Systems Need to Be Unified: Dr Fujino
May 13, 2002
- Abbott Aims at 20th Position in Japan: Mr Liepmann
May 13, 2002
- Debates on Healthcare Reform Start: Diet
May 13, 2002
- Wholesalers Should Take Firm Stance in Price Negotiations: FJPWA
May 13, 2002
- Original Makers to Take Tougher Stance against Patent Infringement
May 13, 2002
- BUSINESS NEWS IN BRIEF
May 13, 2002
- Number of Medical Accidents at Special Function Hospitals Totals over 15,000
May 13, 2002
- Fujisawa: Overseas Sales Exceed \150 Bil.
May 13, 2002
- SSP Licenses Spelear to Han All Pharm in South Korea
April 29, 2002
- Medical Facilities Run by Profit-making Firms to Be Discussed Again
April 29, 2002
- Vital-Net, Ohmori Yakuhin Tohoku to Merge in July
April 29, 2002
- Tokai Univ. Initiates Drug Discovery Project
April 29, 2002
- Animal Study Contracts Increasing: Huntingdon Life Sciences
April 29, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 29, 2002
- BUSINESS NEWS IN BRIEF
April 29, 2002
- Tokyo Katei Yakko Proposes New Distribution for Home Remedies
April 29, 2002
- WEBSITE NEWS
April 29, 2002
- LIFE Corporation to Expand Health Food Product Line
April 29, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
April 29, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…